IOGINALITY
IOGINALITY, the first art NFT platform aimed at emerging galleries, today announced its launch to allow galleries and collectors a seamless and fully compliant platform to transact and benefit from the potential of tokenised art.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005427/en/
IOGINALITY’s interface (Graphic: Business Wire)
Providing emerging galleries with equitable access to resources
With a target of becoming the go-to platform for art market stakeholders worldwide, IOGINALITY’s initial focus is on bringing legal and technical support and resources to young galleries transitioning to the Web3 world, by offering an ecosystem solution and proven legal structure to accelerate new market entrants globally.
IOGINALITY exclusively permits galleries to mint NFTs, guaranteeing that customers deal only with compliant sellers and verified art. In the same vein, IOGINALITY also provides access to trusted buyers by using automated Know-Your-Customer and Know-Your-Business checks, to allow galleries to connect with collectors confidently and provide a trustworthy solution for the financial and legal security of customers’ deals, in line with the ever-evolving regulatory landscape across jurisdictions.
Simplified fee structure for all stakeholders
Powered by smart contracts, IOGINALITY facilitates instantaneous and straightforward transactions for galleries, artists, and art dealers. At the moment of minting, the NFTs’ selling prices and royalties are immediately aligned across all stakeholders, circumventing the costs, obscurities, and delays that often impede innovation. More importantly, the IOGINALITY platform offers the possibility of appointing an unlimited number of receivers involved in the transaction.
Formed under a partnership with Midas Investments, a major international crypto fund based in Hong Kong, IOGINALITY is co-founded by internationally-renowned lawyers Ekaterina Smirnova, and Yuriy Brisov. Together, they bring extensive experience in digital markets, delivering legal, economic and strategic consulting services, as well as a critical awareness of crypto, NFT and securities regulations.
Commenting on the launch, Ekaterina Smirnova, Founder and CEO, said: “IOGINALITY was established as a direct remedy to the common issues facing the NFT market surrounding a lack of transparency, susceptibility to fraud and laundering as well as equitable access to forward-looking legal support resources. As hype around NFTs fades and the professionals remain, the industry is ripe for fundamental transformation. Emerging galleries are repeatedly expressing a keen desire to embrace Web3 and it is important that the industry creates the necessary hand railings to enable their adoption, while setting the standard for accessibility, professionalism, security and trust. IOGINALITY addresses this by levelling the playing field to allow more galleries to join the digital revolution, ushering in a new world order characterised by greater representation.”
Participation from global emerging galleries
At launch, IOGINALITY will first feature collections from Alisa Gallery, a contemporary art gallery in Dubai, imnotART, Chicago’s first NFT art gallery, as well as Web3 creative studio, Wizara. These partnerships allow IOGINALITY to accelerate the market entry of galleries globally, as part of its core mission to enrich an asymmetrical and closed world with quality digital art from all corners of the world. This global presence will be further facilitated by IOGINALITY’s growing network of NFT art ambassadors, who will drive new partnerships between art institutions, brands, and advertisers.
Adham Hafez, Co-founder, Creative Director, and Curator of Wizara added: “As a theorist and a curator, I have been interested in the fact that many legal scholars have moved to study Web3 and engage with how its potentials will radically not only change our understanding of art, but of society and how it manifests itself legally, artistically, politically, and culturally in general. Wizara sees in IOGINALITY a perfect partner in how it straddles an interest in practice as well as in theory, the way it equally invests in not only supporting artists to break through the market, but equally to assist them in understanding the contractual and legal matters of a world governed by Smart-contracts and blockchain-based agreements that will redefine art economy, and many of the gallerist-artists relations in our art worlds today.”
In line with its public launch, IOGINALITY has also launched an open source page ‘NFT Nightmares: Lessons Learned’. Hosted on the IOGINALITY website, the page features key takeaways from high-profile cases of Web3 fraud and malpractice including the stealing of Banksy’s Morons in 2021, and the infamous Hermes vs Rothschld lawsuit, which have deterred many collectors and galleries from exploring this realm. Open for all to participate in and submit personal experiences to feature in the case library, IOGINALITY’s comprehensive platform serves to contribute to the development and betterment of the Web3 community by increasing transparency and awareness of potential pitfalls.
In the long-term, IOGINALITY intends to expand its project and leverage its cross-industry expertise across art, culture, finance, technology, law and project management to implement NFT solutions across markets covering assets such as gems, collectible wines and real estate.
ENDS
About IOGINALITY
IOGINALITY is a digital art marketplace that combines the convenience of the Web3 world with the safety of art dealerships from top galleries and curators to allow artists, institutions, and collectors to transact and benefit from the potential of tokenised art on an accessible, seamless, and fully compliant platform. Through its focus on professionalism and artistic value, IOGINALITY’s platform serves to provide an ecosystem solution to industry concerns around legal, financial and technological facets.
Designed to facilitate greater representation of emerging galleries, IOGINALITY is reimagining the NFT art sector to become the go-to platform for art institutions and stakeholders worldwide to launch digital exhibitions and create NFT collections.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005427/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom